Evidence map›Paper›PMID 42249645›Full record

ArticleAdvanced materials (Deerfield Beach, Fla.)2026

Silk-Based Protein Corona Enhances mRNA-LNP Vaccine Efficacy and Prevents Tumor Relapse.

Shangyuan Cui, Zhongfeng Ye, Mariah L Arral, Lihan Liu, Benson Weng, Xiaohan Zhang, Remya Nair, Yuchen Zhao, Jugal Kishore Sahoo, Shuliang Gao and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced materials (Deerfield Beach, Fla.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Shangyuan CuiDepartment of Biomedical Engineering, Tufts University, Medford, Massachusetts, USA.
Zhongfeng YeDepartment of Biomedical Engineering, Tufts University, Medford, Massachusetts, USA.
Mariah L ArralDepartment of Biomedical Engineering, Tufts University, Medford, Massachusetts, USA.
Lihan LiuDepartment of Biomedical Engineering, Tufts University, Medford, Massachusetts, USA.
Benson WengDepartment of Biomedical Engineering, Tufts University, Medford, Massachusetts, USA.
Xiaohan ZhangDepartment of Biomedical Engineering, Tufts University, Medford, Massachusetts, USA.
Remya NairHarvard Cryo Electron Microscopy Center For Structural Biology, Harvard Medical School, Boston, Massachusetts, USA.
Yuchen ZhaoDepartment of Biomedical Engineering, Tufts University, Medford, Massachusetts, USA.
Jugal Kishore SahooDepartment of Biomedical Engineering, Tufts University, Medford, Massachusetts, USA.
Shuliang GaoDepartment of Biomedical Engineering, Tufts University, Medford, Massachusetts, USA.
Yushu WangDepartment of Biomedical Engineering, Tufts University, Medford, Massachusetts, USA.
Zhiyuan QuDepartment of Biomedical Engineering, Tufts University, Medford, Massachusetts, USA.
Zhongyang ShiDepartment of Biomedical Engineering, Tufts University, Medford, Massachusetts, USA.
Qiaobing XuDepartment of Biomedical Engineering, Tufts University, Medford, Massachusetts, USA.
David L KaplanDepartment of Biomedical Engineering, Tufts University, Medford, Massachusetts, USA.ORCID https://orcid.org/0000-0002-9245-7774

Funding

Tissue Engineering Resource Center: TTDP41EB027062 · NIBIB · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Gordana Vunjak-Novakovic · 2019 to 2026
$12.6M
Tufts IRACDAK12GM133314 · NIGMS · TUFTS UNIVERSITY BOSTON · PI CLAIRE L MOORE, Jamie Lynn Maguire · 2019 to 2026
$8.4M
NIBIB NIH HHS P41 EB027062NIGMS NIH HHS K12 GM133314NIGMS NIH HHS K12GM133314NIH HHS P41EB027062U.S. Army Research Office W911NF-23-1-0276
6 · The paper itself

Abstract

Lipid nanoparticles (LNPs) are clinically validated carriers for nucleic acid therapeutics; however, achieving targeted delivery to reticuloendothelial organs beyond the liver, lung, and spleen remains a major challenge. Here, we introduce a strategy for post-fabrication engineering of a custom protein corona on mRNA-LNPs using cationic silk fibroin (SF), a biocompatible and chemically tunable protein polymer. SF-coated LNPs exhibit enhanced cellular uptake and endosomal escape, resulting in a 3.6 fold increase in lymph node delivery and a 2.5 fold extension in in vivo protein expression compared to unmodified LNPs. In a cancer vaccine model, SF-LNPs significantly improve dendritic cell maturation, antigen cross-presentation, and cytotoxic T cell activation, leading to robust protection against tumor growth and metastasis, as well as durable immunological memory. This work expands the formulation space for LNPs and establishes silk fibroin as a modular surface engineering tool for enhancing the efficacy and specificity of mRNA-based therapeutics.

Indexed as

Cancer VaccinesFibroinsLipidsNanoparticlesProtein CoronaRNA, MessengerSilkAnimalsCell Line, TumorDendritic CellsHumansLiposomesMiceNanovaccinesCancer VaccinesFibroinsLipid NanoparticlesLipidsLiposomesNanovaccinesProtein CoronaRNA, MessengerSilkfifth component LNPslipid nanoparticleslymph node‐targeting deliverymRNA deliveryprotein corona

Identifiers

PMID42249645
PMCPMC13361158

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.